Logo image of AZN

ASTRAZENECA PLC-SPONS ADR (AZN) Stock Fundamental Analysis

NASDAQ:AZN - Nasdaq - US0463531089 - ADR - Currency: USD

70.53  +0.15 (+0.21%)

Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to AZN. AZN was compared to 197 industry peers in the Pharmaceuticals industry. While AZN belongs to the best of the industry regarding profitability, there are concerns on its financial health. AZN scores decently on growth, while it is valued quite cheap. This could make an interesting combination.


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

AZN had positive earnings in the past year.
In the past year AZN had a positive cash flow from operations.
Each year in the past 5 years AZN has been profitable.
Each year in the past 5 years AZN had a positive operating cash flow.
AZN Yearly Net Income VS EBIT VS OCF VS FCFAZN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

1.2 Ratios

The Return On Assets of AZN (7.31%) is better than 90.86% of its industry peers.
With an excellent Return On Equity value of 18.94%, AZN belongs to the best of the industry, outperforming 91.88% of the companies in the same industry.
With an excellent Return On Invested Capital value of 14.10%, AZN belongs to the best of the industry, outperforming 90.86% of the companies in the same industry.
AZN had an Average Return On Invested Capital over the past 3 years of 11.62%. This is significantly below the industry average of 42.34%.
The 3 year average ROIC (11.62%) for AZN is below the current ROIC(14.10%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 7.31%
ROE 18.94%
ROIC 14.1%
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
AZN Yearly ROA, ROE, ROICAZN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20

1.3 Margins

AZN has a Profit Margin of 14.14%. This is amongst the best in the industry. AZN outperforms 90.36% of its industry peers.
In the last couple of years the Profit Margin of AZN has grown nicely.
AZN has a Operating Margin of 24.05%. This is amongst the best in the industry. AZN outperforms 89.34% of its industry peers.
AZN's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 82.36%, AZN belongs to the top of the industry, outperforming 87.31% of the companies in the same industry.
AZN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 24.05%
PM (TTM) 14.14%
GM 82.36%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
AZN Yearly Profit, Operating, Gross MarginsAZN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

3

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AZN is creating some value.
Compared to 1 year ago, AZN has about the same amount of shares outstanding.
Compared to 5 years ago, AZN has more shares outstanding
Compared to 1 year ago, AZN has a worse debt to assets ratio.
AZN Yearly Shares OutstandingAZN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B
AZN Yearly Total Debt VS Total AssetsAZN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B 100B

2.2 Solvency

AZN has an Altman-Z score of 2.97. This is not the best score and indicates that AZN is in the grey zone with still only limited risk for bankruptcy at the moment.
AZN's Altman-Z score of 2.97 is fine compared to the rest of the industry. AZN outperforms 75.13% of its industry peers.
AZN has a debt to FCF ratio of 3.46. This is a good value and a sign of high solvency as AZN would need 3.46 years to pay back of all of its debts.
AZN has a Debt to FCF ratio of 3.46. This is amongst the best in the industry. AZN outperforms 89.34% of its industry peers.
AZN has a Debt/Equity ratio of 0.71. This is a neutral value indicating AZN is somewhat dependend on debt financing.
AZN's Debt to Equity ratio of 0.71 is on the low side compared to the rest of the industry. AZN is outperformed by 65.99% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF 3.46
Altman-Z 2.97
ROIC/WACC1.65
WACC8.56%
AZN Yearly LT Debt VS Equity VS FCFAZN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

2.3 Liquidity

A Current Ratio of 0.90 indicates that AZN may have some problems paying its short term obligations.
AZN has a worse Current ratio (0.90) than 84.26% of its industry peers.
AZN has a Quick Ratio of 0.90. This is a bad value and indicates that AZN is not financially healthy enough and could expect problems in meeting its short term obligations.
AZN has a Quick ratio of 0.70. This is amonst the worse of the industry: AZN underperforms 85.79% of its industry peers.
Industry RankSector Rank
Current Ratio 0.9
Quick Ratio 0.7
AZN Yearly Current Assets VS Current LiabilitesAZN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 18.27% over the past year.
Measured over the past years, AZN shows a quite strong growth in Earnings Per Share. The EPS has been growing by 18.59% on average per year.
AZN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.48%.
AZN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.27% yearly.
EPS 1Y (TTM)18.27%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%25.73%
Revenue 1Y (TTM)15.48%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%7.17%

3.2 Future

Based on estimates for the next years, AZN will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.41% on average per year.
The Revenue is expected to grow by 6.41% on average over the next years.
EPS Next Y12.48%
EPS Next 2Y12.94%
EPS Next 3Y11.87%
EPS Next 5Y11.41%
Revenue Next Year8.37%
Revenue Next 2Y7.23%
Revenue Next 3Y6.74%
Revenue Next 5Y6.41%

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
AZN Yearly Revenue VS EstimatesAZN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20B 40B 60B
AZN Yearly EPS VS EstimatesAZN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2 4 6

7

4. Valuation

4.1 Price/Earnings Ratio

AZN is valuated correctly with a Price/Earnings ratio of 16.03.
Based on the Price/Earnings ratio, AZN is valued cheaper than 84.77% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.17. AZN is valued slightly cheaper when compared to this.
The Price/Forward Earnings ratio is 13.38, which indicates a correct valuation of AZN.
Based on the Price/Forward Earnings ratio, AZN is valued cheaper than 82.23% of the companies in the same industry.
AZN's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.10.
Industry RankSector Rank
PE 16.03
Fwd PE 13.38
AZN Price Earnings VS Forward Price EarningsAZN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AZN indicates a rather cheap valuation: AZN is cheaper than 82.23% of the companies listed in the same industry.
AZN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. AZN is cheaper than 81.73% of the companies in the same industry.
Industry RankSector Rank
P/FCF 23.93
EV/EBITDA 12.18
AZN Per share dataAZN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15

4.3 Compensation for Growth

AZN's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
AZN has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)1.28
PEG (5Y)0.86
EPS Next 2Y12.94%
EPS Next 3Y11.87%

6

5. Dividend

5.1 Amount

AZN has a Yearly Dividend Yield of 2.34%.
Compared to an average industry Dividend Yield of 4.20, AZN pays a better dividend. On top of this AZN pays more dividend than 92.39% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.40, AZN has a dividend comparable with the average S&P500 company.
Industry RankSector Rank
Dividend Yield 2.34%

5.2 History

The dividend of AZN has a limited annual growth rate of 1.40%.
AZN has been paying a dividend for at least 10 years, so it has a reliable track record.
AZN has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)1.4%
Div Incr Years1
Div Non Decr Years11
AZN Yearly Dividends per shareAZN Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.5 1

5.3 Sustainability

63.60% of the earnings are spent on dividend by AZN. This is not a sustainable payout ratio.
The dividend of AZN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP63.6%
EPS Next 2Y12.94%
EPS Next 3Y11.87%
AZN Yearly Income VS Free CF VS DividendAZN Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B
AZN Dividend Payout.AZN Dividend Payout, showing the Payout Ratio.AZN Dividend Payout.PayoutRetained Earnings

ASTRAZENECA PLC-SPONS ADR

NASDAQ:AZN (5/29/2025, 9:54:09 AM)

70.53

+0.15 (+0.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)04-29 2025-04-29/bmo
Earnings (Next)07-29 2025-07-29/bmo
Inst Owners47.67%
Inst Owner Change-1.12%
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap218.67B
Analysts82.29
Price Target93.58 (32.68%)
Short Float %0.16%
Short Ratio0.8
Dividend
Industry RankSector Rank
Dividend Yield 2.34%
Yearly Dividend2.99
Dividend Growth(5Y)1.4%
DP63.6%
Div Incr Years1
Div Non Decr Years11
Ex-Date02-21 2025-02-21 (1.05)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.54%
Min EPS beat(2)-0.63%
Max EPS beat(2)13.71%
EPS beat(4)2
Avg EPS beat(4)2.95%
Min EPS beat(4)-1.9%
Max EPS beat(4)13.71%
EPS beat(8)5
Avg EPS beat(8)2.79%
EPS beat(12)9
Avg EPS beat(12)4.04%
EPS beat(16)11
Avg EPS beat(16)2.71%
Revenue beat(2)1
Avg Revenue beat(2)-0.64%
Min Revenue beat(2)-3.99%
Max Revenue beat(2)2.7%
Revenue beat(4)2
Avg Revenue beat(4)-0.21%
Min Revenue beat(4)-3.99%
Max Revenue beat(4)2.7%
Revenue beat(8)4
Avg Revenue beat(8)-0.19%
Revenue beat(12)4
Avg Revenue beat(12)-0.55%
Revenue beat(16)8
Avg Revenue beat(16)0.72%
PT rev (1m)0.98%
PT rev (3m)10.84%
EPS NQ rev (1m)-0.08%
EPS NQ rev (3m)-0.36%
EPS NY rev (1m)-0.32%
EPS NY rev (3m)-0.69%
Revenue NQ rev (1m)0.15%
Revenue NQ rev (3m)1.49%
Revenue NY rev (1m)0.27%
Revenue NY rev (3m)0.9%
Valuation
Industry RankSector Rank
PE 16.03
Fwd PE 13.38
P/S 3.98
P/FCF 23.93
P/OCF 16.71
P/B 5.33
P/tB N/A
EV/EBITDA 12.18
EPS(TTM)4.4
EY6.24%
EPS(NY)5.27
Fwd EY7.48%
FCF(TTM)2.95
FCFY4.18%
OCF(TTM)4.22
OCFY5.99%
SpS17.73
BVpS13.24
TBVpS-5.69
PEG (NY)1.28
PEG (5Y)0.86
Profitability
Industry RankSector Rank
ROA 7.31%
ROE 18.94%
ROCE 17.15%
ROIC 14.1%
ROICexc 15.14%
ROICexgc 76.66%
OM 24.05%
PM (TTM) 14.14%
GM 82.36%
FCFM 16.62%
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
ROICexc(3y)12.66%
ROICexc(5y)10.55%
ROICexgc(3y)112.76%
ROICexgc(5y)85.06%
ROCE(3y)13.95%
ROCE(5y)11.45%
ROICexcg growth 3Y43.28%
ROICexcg growth 5Y4.77%
ROICexc growth 3Y41%
ROICexc growth 5Y11.99%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
F-Score9
Asset Turnover0.52
Health
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF 3.46
Debt/EBITDA 1.47
Cap/Depr 58.81%
Cap/Sales 7.18%
Interest Coverage 9.49
Cash Conversion 65.63%
Profit Quality 117.58%
Current Ratio 0.9
Quick Ratio 0.7
Altman-Z 2.97
F-Score9
WACC8.56%
ROIC/WACC1.65
Cap/Depr(3y)61.87%
Cap/Depr(5y)60.41%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.64%
Profit Quality(3y)144.6%
Profit Quality(5y)772.45%
High Growth Momentum
Growth
EPS 1Y (TTM)18.27%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%25.73%
EPS Next Y12.48%
EPS Next 2Y12.94%
EPS Next 3Y11.87%
EPS Next 5Y11.41%
Revenue 1Y (TTM)15.48%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%7.17%
Revenue Next Year8.37%
Revenue Next 2Y7.23%
Revenue Next 3Y6.74%
Revenue Next 5Y6.41%
EBIT growth 1Y42.22%
EBIT growth 3Y37.28%
EBIT growth 5Y27.35%
EBIT Next Year34.44%
EBIT Next 3Y17.32%
EBIT Next 5Y13.31%
FCF growth 1Y51.52%
FCF growth 3Y24.58%
FCF growth 5Y70.22%
OCF growth 1Y34.8%
OCF growth 3Y25.76%
OCF growth 5Y31.92%